NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Day One Biopharmaceuticals, Inc. (DAWN) Stock Analysis

Day One Biopharmaceuticals, Inc. (DAWN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

DAWN

$21.53

$0.00 (0.00%)

Last trade April 24, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DAWN with… →

DAWN Key Statistics

As of Apr 24, 2026
Trading
Open
$21.53
Previous Close
$21.53
52-Week Range
5.64–21.53
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−1.75
Valuation
Market Cap
$2.22B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
14.06
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.04
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
−67.85%
1-Year Return
+172.53%
Dividend and dates
Avg Volume
3.93M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

DAWN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+131.01%
2025−26.44%
2024 (partial year)+1.69%

As of April 24, 2026.

DAWN Valuation vs Biotechnology Median

Median of 656 stocks
MetricDAWNBiotechnology medianvs median
P/S ratio14.0615.268% below
Profit margin−67.85%0.00%67.8 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Day One Biopharmaceuticals, Inc. (DAWN) carries a market capitalisation of $2.22B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 178.

DAWN last closed at $21.53 on April 24, 2026. The close was unchanged from the previous session. Over the past 52 weeks the price has ranged from $5.64 to $21.53. The latest close sits 282.08% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is $158.18M. Profit margin runs at −67.85%. That is 67.8 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −1.04.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 14.06 times revenue. On price-to-sales that is 7.85% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at −1.75. Annualized volatility over the trailing 1 year is 100.2%. Over the trailing twelve months the price has returned +172.53%.

Growth & Income

No dividend is on file for DAWN.

The record holds one complete calendar year, 2025, which returned −26.44%. So far in 2026 the price is +131.01%.

Peer Comparison

Day One Biopharmaceuticals, Inc. (DAWN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Day One Biopharmaceuticals, Inc. DAWN $2.22B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Day One Biopharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of April 24, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral and brain-penetrant type II rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It is also developing DAY301, a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody conjugated with a topoisomerase I inhibitor via a highly stable and hydrophilic modified valine-alanine (VA) cleavable linker for the treatment of patients with advanced solid tumors; and Emi-Le, an antibody-drug conjugate that targets B7- H4 conjugated to an auristatin anti-tubulin payload as a component of a proprietary linker-payload platform developed by Mersana Therapeutics that is in Phase 1 clinicla trial for the treatment of breast cancer, ovarian cancer, endometrial cancer, and adenoid cystic carcinoma (ACC). Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California. As of April 22, 2026, Day One Biopharmaceuticals, Inc. operates as a subsidiary of Servier Pharmaceuticals LLC.

Visit website →